{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:00:16Z","timestamp":1793898016146,"version":"4.8.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000738","name":"Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000960","name":"American College of Rheumatology Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000960","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.berh.2021.101741","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T12:52:07Z","timestamp":1642596727000},"page":"101741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Prediction of treatment response: Personalized medicine in the management of rheumatoid arthritis"],"prefix":"10.1016","volume":"36","author":[{"given":"Monica","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong-Qiu","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.berh.2021.101741_bib1","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"American college of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res"},{"issue":"6","key":"10.1016\/j.berh.2021.101741_bib2","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.berh.2021.101741_bib3","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1080\/17425255.2020.1777279","article-title":"Using pharmacogenetics to predict methotrexate response in rheumatoid arthritis patients","volume":"16","author":"Szostak","year":"2020","journal-title":"Expet Opin Drug Metabol Toxicol"},{"issue":"2","key":"10.1016\/j.berh.2021.101741_bib4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00063030-200923020-00004","article-title":"Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response","volume":"23","author":"Gibbons","year":"2009","journal-title":"BioDrugs"},{"issue":"3","key":"10.1016\/j.berh.2021.101741_bib5","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.rdc.2017.04.008","article-title":"Precision medicine in rheumatoid arthritis","volume":"43","author":"Bluett","year":"2017","journal-title":"Rheum Dis Clin N Am"},{"issue":"5","key":"10.1016\/j.berh.2021.101741_bib6","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/1744666X.2018.1465409","article-title":"Prediction of response to methotrexate in rheumatoid arthritis","volume":"14","author":"Ling","year":"2018","journal-title":"Expet Rev Clin Immunol"},{"issue":"4","key":"10.1016\/j.berh.2021.101741_bib7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/1744666X.2020.1740594","article-title":"Personalized medicine in rheumatic diseases: how close are we to being able to use genetic biomarkers to predict response to TNF inhibitors?","volume":"16","author":"Sutcliffe","year":"2020","journal-title":"Expet Rev Clin Immunol"},{"key":"10.1016\/j.berh.2021.101741_bib8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.intimp.2016.05.012","article-title":"The association between reduced folate carrier-1 gene 80G\/A polymorphism and methotrexate efficacy or methotrexate related-toxicity in rheumatoid arthritis: a meta-analysis","volume":"38","author":"Li","year":"2016","journal-title":"Int Immunopharm"},{"issue":"2","key":"10.1016\/j.berh.2021.101741_bib9","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41397-019-0098-9","article-title":"Predictive genetic biomarkers for the efficacy of methotrexate in rheumatoid arthritis: a systematic review","volume":"20","author":"Eektimmerman","year":"2020","journal-title":"Pharmacogenomics J"},{"issue":"5","key":"10.1016\/j.berh.2021.101741_bib10","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41584-020-0395-3","article-title":"Pharmacomicrobiomics in inflammatory arthritis: gut microbiome as modulator of therapeutic response","volume":"16","author":"Scher","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.berh.2021.101741_bib11","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.01202","article-title":"Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis","volume":"2","author":"Scher","year":"2013","journal-title":"Elife"},{"issue":"8","key":"10.1016\/j.berh.2021.101741_bib12","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/nm.3914","article-title":"The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment","volume":"21","author":"Zhang","year":"2015","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.berh.2021.101741_bib13","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13073-021-00957-0","article-title":"Gut microbial determinants of clinically important improvement in patients with rheumatoid arthritis","volume":"13","author":"Gupta","year":"2021","journal-title":"Genome Med"},{"issue":"6","key":"10.1016\/j.berh.2021.101741_bib14","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/art.41622","article-title":"The pretreatment gut microbiome is associated with lack of response to methotrexate in new-onset rheumatoid arthritis","volume":"73","author":"Artacho","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2021.101741_bib15","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.chom.2020.12.008","article-title":"Methotrexate impacts conserved pathways in diverse human gut bacteria leading to decreased host immune activation","volume":"29","author":"Nayak","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.berh.2021.101741_bib16","doi-asserted-by":"crossref","first-page":"796865","DOI":"10.3389\/fimmu.2021.796865","article-title":"Gut microbiota-medication interaction in rheumatic diseases","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.berh.2021.101741_bib17","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13075-021-02451-9","article-title":"Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment","volume":"23","author":"Oliver","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1016\/j.berh.2021.101741_bib18","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/art.41056","article-title":"Machine learning to predict anti-tumor necrosis factor drug responses of rheumatoid arthritis patients by integrating clinical and genetic markers","volume":"71","author":"Guan","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2021.101741_bib19","article-title":"Early prediction of clinical response to anti-TNF treatment using multi-omics and machine learning in rheumatoid arthritis","author":"Yoosuf","year":"2021","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.berh.2021.101741_bib20","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/art.41516","article-title":"Multiomics and machine learning accurately predict clinical response to adalimumab and etanercept therapy in patients with rheumatoid arthritis","volume":"73","author":"Tao","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2021.101741_bib21","doi-asserted-by":"crossref","first-page":"631662","DOI":"10.3389\/fimmu.2021.631662","article-title":"Integrative clinical, molecular, and computational analysis identify novel biomarkers and differential profiles of anti-TNF response in rheumatoid arthritis","volume":"12","author":"Luque-Tevar","year":"2021","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.berh.2021.101741_bib22","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1002\/art.24913","article-title":"The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study","volume":"60","author":"Klaasen","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.berh.2021.101741_bib23","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/ard.2007.081950","article-title":"Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients","volume":"67","author":"van der Pouw Kraan","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.berh.2021.101741_bib24","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/art.1780340908","article-title":"Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis","volume":"34","author":"Chu","year":"1991","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.berh.2021.101741_bib25","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/art.1780351009","article-title":"Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha","volume":"35","author":"Deleuran","year":"1992","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.berh.2021.101741_bib26","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1136\/ard.2007.080440","article-title":"The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium","volume":"67","author":"Wijbrandts","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.berh.2021.101741_bib27","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1093\/rheumatology\/ken261","article-title":"The value of synovial cytokine expression in predicting the clinical response to TNF antagonist therapy (infliximab)","volume":"47","author":"Buch","year":"2008","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.berh.2021.101741_bib28","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.4049\/jimmunol.167.2.1072","article-title":"Lymphoid neogenesis in rheumatoid synovitis","volume":"167","author":"Takemura","year":"2001","journal-title":"J\u00a0Immunol"},{"issue":"5","key":"10.1016\/j.berh.2021.101741_bib29","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/eji.200425830","article-title":"Systematic microanatomical analysis of CXCL13 and CCL21 in situ production and progressive lymphoid organization in rheumatoid synovitis","volume":"35","author":"Manzo","year":"2005","journal-title":"Eur J Immunol"},{"issue":"3","key":"10.1016\/j.berh.2021.101741_bib30","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/BOR.0b013e32835fd8eb","article-title":"New learnings on the pathophysiology of RA from synovial biopsies","volume":"25","author":"Pitzalis","year":"2013","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2021.101741_bib31","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s11926-011-0201-y","article-title":"Synovial tissue heterogeneity and peripheral blood biomarkers","volume":"13","author":"Bugatti","year":"2011","journal-title":"Curr Rheumatol Rep"},{"issue":"2","key":"10.1016\/j.berh.2021.101741_bib32","doi-asserted-by":"crossref","first-page":"R90","DOI":"10.1186\/ar4555","article-title":"Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics","volume":"16","author":"Dennis","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.berh.2021.101741_bib33","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/annrheumdis-2018-214539","article-title":"Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients","volume":"78","author":"Humby","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.berh.2021.101741_bib34","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1016\/j.celrep.2019.07.091","article-title":"Molecular portraits of early rheumatoid arthritis identify clinical and treatment response phenotypes","volume":"28","author":"Lewis","year":"2019","journal-title":"Cell Rep"},{"issue":"5","key":"10.1016\/j.berh.2021.101741_bib35","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/art.40428","article-title":"Identification of three rheumatoid arthritis disease subtypes by machine learning integration of synovial histologic features and RNA sequencing data","volume":"70","author":"Orange","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2021.101741_bib36","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3389\/fimmu.2020.00845","article-title":"A\u00a0pauci-immune synovial pathotype predicts inadequate response to TNFalpha-blockade in rheumatoid arthritis patients","volume":"11","author":"Nerviani","year":"2020","journal-title":"Front Immunol"},{"issue":"10271","key":"10.1016\/j.berh.2021.101741_bib37","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0140-6736(20)32341-2","article-title":"Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial","volume":"397","author":"Humby","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.berh.2021.101741_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011310","article-title":"The gene expression profile in the synovium as a predictor of the clinical response to infliximab treatment in rheumatoid arthritis","volume":"5","author":"Lindberg","year":"2010","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.berh.2021.101741_bib39","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/s41591-020-0939-8","article-title":"Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis","volume":"26","author":"Alivernini","year":"2020","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.berh.2021.101741_bib40","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/art.40453","article-title":"Transcriptional profiling of synovial macrophages using minimally invasive ultrasound-guided synovial biopsies in rheumatoid arthritis","volume":"70","author":"Mandelin","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2021.101741_bib41","article-title":"Complex machine-learning algorithms and multivariable logistic regression on par in the prediction of insufficient clinical response to methotrexate in rheumatoid arthritis","volume":"11","author":"Gosselt","year":"2021","journal-title":"J\u00a0Personalized Med"},{"key":"10.1016\/j.berh.2021.101741_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2019.03.002","article-title":"Compendium of synovial signatures identifies pathologic characteristics for predicting treatment response in rheumatoid arthritis patients","volume":"202","author":"Kim","year":"2019","journal-title":"Clin Immunol"},{"issue":"8","key":"10.1016\/j.berh.2021.101741_bib43","article-title":"Inference of an integrative, executable network for rheumatoid arthritis combining data-driven machine learning approaches and a state-of-the-art mechanistic disease map","volume":"11","author":"Miagoux","year":"2021","journal-title":"J\u00a0Personalized Med"},{"issue":"1","key":"10.1016\/j.berh.2021.101741_bib44","doi-asserted-by":"crossref","first-page":"7907","DOI":"10.1038\/s41598-020-64431-4","article-title":"Synovial tissue transcriptomes of long-standing rheumatoid arthritis are dominated by activated macrophages that reflect microbial stimulation","volume":"10","author":"Smiljanovic","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.berh.2021.101741_bib45","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41467-018-02892-y","article-title":"Functionally distinct disease-associated fibroblast subsets in rheumatoid arthritis","volume":"9","author":"Mizoguchi","year":"2018","journal-title":"Nat Commun"},{"issue":"7751","key":"10.1016\/j.berh.2021.101741_bib46","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41586-019-1049-y","article-title":"Transcriptome-scale super-resolved imaging in tissues by RNA seqFISH","volume":"568","author":"Eng","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.berh.2021.101741_bib47","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41584-020-00538-2","article-title":"Machine learning in precision medicine: lessons to learn","volume":"17","author":"Plant","year":"2021","journal-title":"Nat Rev Rheumatol"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694221000838?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694221000838?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:21:47Z","timestamp":1761499307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694221000838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S1521694221000838"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2021.101741","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prediction of treatment response: Personalized medicine in the management of rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2021.101741","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101741"}}